Pathologic concordance between prostate biopsy and radical prostatectomy improves with use of a novel robotic-assisted transperineal fusion biopsy platform. Optimization of risk stratification at ...

Verana Health ®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world ...

Advanced age raises mortality risk in metastatic prostate cancer. Learn how PSA, tumour grade, and treatment influence ...

Artera has secured CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for its ArteraAI prostate ...

This Special Article provides a comprehensive review and expert commentary on the prospective clinical implementation of artificial intelligence (AI) in the detection of prostate cancer from digital ...

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer. AUSTIN, ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

Development and validation of computational histology artificial intelligence (CHAI)–powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET ...

A new study designs drugs that bind to intrinsically disordered proteins that are extremely difficult to target due to their flexible nature.

New research outlines an enhanced approach that could lead to treatments for prostate cancer and other diseases.

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered ...